Cancer Genetics, Inc. (CGIX)
(Delayed Data from NSDQ)
$0.22 USD
-0.01 (-3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.23 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.22 USD
-0.01 (-3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.23 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Company News for Aug 25, 2020
by Zacks Equity Research
Companies in the news are: ZM, AXAS, CGIX, BWAY
LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space
by Zacks Equity Research
The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.
Cancer Genetics (CGIX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cancer Genetics (CGIX) delivered earnings and revenue surprises of -43.75% and -26.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Cancer Genetics (CGIX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cancer Genetics (CGIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc Announces Stock Sale to Finance Growing Business
by Zacks Equity Research
Teladoc Inc. (TDOC) has announced to sell 5,400,000 shares of its common stock, in an effort to procure funds for expansion.
Teladoc's Client UnitedAg Expands Pact to Get Wider Services
by Zacks Equity Research
Teladoc Inc.'s (TDOC) existing client UnitedAg has expanded its partnership with the former.
The Advisory Board (ABCO) in Focus: Stock Surges 16.2%
by Zacks Equity Research
The Advisory Board Company (ABCO) was a big mover last session, as the company saw its shares surged over 16% on the day.
VCA Looks to Gain Scale and Size by Being Part of Mars
by Zacks Equity Research
VCA Inc. (WOOF), a provider of pet health care services in the U.S., has agreed to be acquired by Mars, Incorporated.
Teladoc (TDOC) Guidance Reflects Solid Business in '16, '17
by Zacks Equity Research
Teladoc's (TDOC), upbeat guidance for 2016 and 2017 points to strong business growth and superior performance.